<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="Publisher" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">37794819</PMID><DateRevised><Year>2023</Year><Month>10</Month><Day>05</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1029-2403</ISSN><JournalIssue CitedMedium="Internet"><PubDate><Year>2023</Year><Month>Oct</Month><Day>05</Day></PubDate></JournalIssue><Title>Leukemia &amp; lymphoma</Title><ISOAbbreviation>Leuk Lymphoma</ISOAbbreviation></Journal><ArticleTitle>Use of PD-1 blockade in refractory/relapsed natural killer T-cell lymphomas: a systematic review and synthesis of case reports.</ArticleTitle><Pagination><StartPage>1</StartPage><EndPage>11</EndPage><MedlinePgn>1-11</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1080/10428194.2023.2264431</ELocationID><Abstract><AbstractText>Natural killer/T-cell lymphoma (NK/T-cellL) is an aggressive non-Hodgkin's lymphoma with limited treatment options for patients who experience disease progression or recurrence after second-line treatment. The use of new therapies, such as pembrolizumab, which involves immune checkpoint blockade mechanisms, is proposed. This systematic review followed the MOSE guidelines and searched PUBMED/MEDLINE, EMBASE, and Scopus databases. Fourteen articles were found, reporting on the use of pembrolizumab anti PD-1 in NK/T-cellL patients. The objective response rate was 84.50%, with disease-free survival ranging from two to 48&#x2009;months. The complete response rate was 61.6%, and the quality of the reported studies was evaluated to be of high and moderate confidence bias levels in case reports and high bias in clinical trials. Pembrolizumab and others anti PD-1 are treatment options for refractory/recurrent NK/T-cellL, regardless of PD-L1 expression, with good short- and long-term results and low adverse events.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Rivera-Francia</LastName><ForeName>Victor M</ForeName><Initials>VM</Initials><AffiliationInfo><Affiliation>ALIADA Centro Oncol&#xf3;gico, Lima, Peru.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Failoc-Rojas</LastName><ForeName>Virgilio E</ForeName><Initials>VE</Initials><Identifier Source="ORCID">0000-0003-2992-9342</Identifier><AffiliationInfo><Affiliation>ALIADA Centro Oncol&#xf3;gico, Lima, Peru.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Universidad San Ignacio de Loyola, Lima, Peru.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Villacorta-Carranza</LastName><ForeName>Robert</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>ALIADA Centro Oncol&#xf3;gico, Lima, Peru.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Leon Garrido-Lecca</LastName><ForeName>Alejandro</ForeName><Initials>A</Initials><Identifier Source="ORCID">0009-0007-7137-0083</Identifier><AffiliationInfo><Affiliation>ALIADA Centro Oncol&#xf3;gico, Lima, Peru.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Calle-Villavicencio</LastName><ForeName>Ana</ForeName><Initials>A</Initials><Identifier Source="ORCID">0009-0001-0705-1981</Identifier><AffiliationInfo><Affiliation>ALIADA Centro Oncol&#xf3;gico, Lima, Peru.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Torres-Mera</LastName><ForeName>Alicia</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0002-6729-9372</Identifier><AffiliationInfo><Affiliation>Universidad Nacional Pedro Ruiz Gallo, Lambayeque, Peru.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Valladares-Garido</LastName><ForeName>Mario J</ForeName><Initials>MJ</Initials><Identifier Source="ORCID">0000-0003-0839-2419</Identifier><AffiliationInfo><Affiliation>Universidad Continental, Lima, Peru.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Huerta-Collado</LastName><ForeName>Yesenia</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>ALIADA Centro Oncol&#xf3;gico, Lima, Peru.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Motta-Guerrero</LastName><ForeName>Rodrigo</ForeName><Initials>R</Initials><Identifier Source="ORCID">0000-0002-8086-3513</Identifier><AffiliationInfo><Affiliation>ALIADA Centro Oncol&#xf3;gico, Lima, Peru.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Casanova Marquez</LastName><ForeName>Luis</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>ALIADA Centro Oncol&#xf3;gico, Lima, Peru.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>10</Month><Day>05</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Leuk Lymphoma</MedlineTA><NlmUniqueID>9007422</NlmUniqueID><ISSNLinking>1026-8022</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Lymphoma</Keyword><Keyword MajorTopicYN="N">NK-T-cell</Keyword><Keyword MajorTopicYN="N">immune checkpoint inhibitors (DeCS-BIREME)</Keyword><Keyword MajorTopicYN="N">programmed cell death 1 receptor</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>10</Month><Day>5</Day><Hour>6</Hour><Minute>44</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>10</Month><Day>5</Day><Hour>6</Hour><Minute>44</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>10</Month><Day>5</Day><Hour>3</Hour><Minute>51</Minute></PubMedPubDate></History><PublicationStatus>aheadofprint</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">37794819</ArticleId><ArticleId IdType="doi">10.1080/10428194.2023.2264431</ArticleId></ArticleIdList></PubmedData></PubmedArticle></PubmedArticleSet>